First Read: China Healthcare "ESMO 2026 Preview: Top 15 ordinary abstracts..."

Research evidence excerpt

First Read: China Healthcare "ESMO 2026 Preview: Top 15 ordinary abstracts..."

Global Research

20 July 2026ab

First Read

EquitiesChina Healthcare

ESMO 2026 Preview: Top 15 ordinary abstracts China

to watch across China biopharma coverage Healthcare

Chen Chen, PhD

Analyst

chen-zb.chen@ubs.com

The ESMO 2026 Annual Congress will commence on 23 October 2026 in Spain. Titles of +86-10-5832 8201

ordinary abstracts have now been officially released, while the titles of Late-Breaking

Anita Wei

Abstracts (LBAs) are expected to be disclosed on 25 September. We note that China's Analyst

contributions to ESMO 2026 are largely centered around ADCs and PD-1/VEGF anita.wei@ubs.com

bispecifics, underscoring the continued evolution of China's innovative oncology +852-2971 7459

pipeline.

David Guo, PhD

Within our coverage universe, we have identified 10 highly anticipated abstracts that are S1460524040001

likely to serve as key catalysts for the sector. Regarding the LBAs, we are expecting david-za.guo@ubs.com

potential inclusion of Kelun Biotech's sac-TMT China phase 3 data in 1L TNBC and 1L +86-10-5832 8010

nsqNSCLC (TPS<1%). Liz Han, CFA

liz.han@ubs.com

BsAb space-

+852-2971 6106

1. Innovent | Oral | 24 Oct: IBI363 (TAK-928) plus bevacizumab (Bev) vs docetaxel

(DTX) in patients (pts) with locally advanced or metastatic immunotherapy (IO)-resistant

lung adenocarcinoma (LUAC) without actionable genomic alterations: a randomized

phase Ib study

2. BeOne | Oral | 26 Oct: Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific

antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation

(DE) Update in Advanced Hepatocellular Carcinoma (HCC)

3. 3SBio | Poster | 26 Oct: Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-